Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results

    Research output: Contribution to journalLetterpeer-review

  2. Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. [Sar1, Ile4, Ile8]-angiotensin II Potentiates Insulin Receptor Signalling and Glycogen Synthesis in Hepatocytes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Serum and cerebrospinal fluid neurofilament levels predict longitudinal atrophy of the cervical spinal cord in progressive MS

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Although immunosuppressants in the treatment of myasthenia have been available for several decades, population-based studies describing drug utilization in myasthenia patients are scarce. We aimed in this study to describe the treatment of myasthenia in Denmark in more recent years with emphasis on use of oral immunosuppressant agents. We identified a nationwide cohort of incident myasthenia patients in Denmark from 1996 to 2013 and tracked their use of drugs over the entire period using data from nationwide registers. Patients with myasthenia were classified according to utilization of specific immunosuppressants (e.g. prednisolone) as 'never user' or 'ever user'. We used Kaplan-Meier (K-M) and proportion of patients covered (PPC) curves to describe treatment onset and termination. We identified 928 patients (52% female) with incident myasthenia in the study period. Overall, 638 (69%) were treated with prednisolone and 506 (55%) with azathioprine. Treatment with prednisolone and azathioprine within 2 years of myasthenia diagnosis was initiated in 462 (56%) and 366 (45%). Only one of four myasthenia patients (n = 231) did not receive oral immunosuppressive treatment at any time in the study period. Prednisolone was stopped in most patients, whereas treatment with azathioprine was often continued throughout follow-up. In conclusion, we found that treatment of myasthenia in Denmark in recent years corresponded well to the expected clinical course of myasthenia and that most patients underwent long-term immunosuppression.

Original languageEnglish
JournalBasic & clinical pharmacology & toxicology
Volume123
Issue number4
Pages (from-to)486-493
Number of pages8
ISSN1742-7843
DOIs
Publication statusPublished - Oct 2018

    Research areas

  • Administration, Oral, Age of Onset, Aged, Denmark/epidemiology, Drug Prescriptions, Drug Utilization Review, Female, Health Care Surveys, Humans, Immunosuppressive Agents/administration & dosage, Incidence, Male, Middle Aged, Myasthenia Gravis/diagnosis, Practice Patterns, Physicians'/trends, Registries, Time Factors, Treatment Outcome

ID: 56324217